Trial Profile
A Multi-center, Long-term, Open-label Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Esreboxetine (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Pharmacogenomic; Registrational
- Sponsors Pfizer
- 24 Dec 2021 This trial has been completed in Czechia, according to European Clinical Trials Database.
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 04 Jul 2012 Planned number of patients changed from 500 to 550 as reported by EudraCT.